Clinical Trials Browser

Erlotinib Hydrochloride × 90 days × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01708954 2026-05-26

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

125 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00602667 2026-05-19

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Phase 2 Active not recruiting

293 enrolled 89 charts

Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor

NCT01350817 2026-05-15

TARSEQ

Phase 2 Completed

156 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02194738 2026-05-13

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04981509 2026-05-13

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2 Recruiting

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Phase 2 Recruiting

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT02193282 2026-05-04

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04172779 2026-05-01

ECHO-B

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

NCT00883480 2026-04-28

SLAT

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT00885066 2026-04-23

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT06483555 2026-04-23

PANGEA

Phase 1/2 Recruiting

DermatologicGastrointestinal

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT00076310 2026-04-15

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2 Active not recruiting

50 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00045201 2026-04-13

Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Adult Solid Neoplasm

NCT00878163 2026-04-13

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT01660971 2026-04-13

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03403049 2026-04-13

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma